Major players in the artificial intelligence in healthcare market market are Intel Corporation, Nvidia Corporation, IBM Corporation, Microsoft Corporation, Google Inc. , Welltok Inc. , General Vision Inc.

New York, June 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Artificial Intelligence in Healthcare Market Global Market Report 2022" - https://www.reportlinker.com/p06282662/?utm_source=GNW , General Electric Company, Siemens Healthcare Private Limited, Medtronic, Koninklijke Philips N.V., Micron Technology Inc., Johnson & Johnson Services Inc., Next IT Corporation, and Amazon Web Services. The global artificial intelligence in healthcare market is expected to grow from $8.19 billion in 2021 to $10.11 billion in 2022 at a compound annual growth rate (CAGR) of 23.46%. The market is expected to grow to $49.10 billion in 2026 at a CAGR of 48.44%. The Artificial Intelligence in Healthcare market consists of sales of artificial intelligence in healthcare products and related services by entities (organizations, sole proprietors, partnerships) that use AI to treat various medical conditions in patients.Artificial intelligence is the use of machine learning and cognitive algorithms for treatment techniques and patient outcomes. AI is applied in various healthcare practices such as medical diagnostics, drug discovery, clinical trials, pain management, and improving patient outcomes. The main types of AI in healthcare offerings include hardware and software.By algorithms, types of AI in healthcare products include deep learning, querying method, natural language processing, and context aware processing. Medical device manufacturers use AI-based technologies to innovate hardware products to better assist health care providers and improve the treatment.Technology companies develop AI algorithms for healthcare-related solutions. The major applications of AI in healthcare are robot-assisted surgery, virtual nursing assistant, administrative workflow assistance, fraud detection, dosage error reduction, clinical trial participant identifier, and preliminary diagnosis. Major end users of AI in healthcare are hospitals and diagnostic centers, pharmaceutical and biopharmaceutical companies, healthcare payers, and patients. North America was the largest region in the Artificial Intelligence in Healthcare market in 2021.Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The increase in the adoption of precision medicine is one of the driving factors of the artificial intelligence in healthcare market.Precision medicine uses information of an individual gene, environmental and lifestyles changes to design and improve the diagnosis, therapeutics of the patient It is widely used for oncology cases, and due to the rising prevalence of cancer, and people affected by it, the demand for AI in precision medicine will increase growing forward. According to a research published in the Lancet Oncology, the global cancer burden is set to increase 75% by 2030. AI-driven surgical robots are an emerging trend in the artificial intelligence in healthcare market.Various healthcare fields have adopted robotic surgery in recent times. Robots-assisted surgeries are performed to eliminate the limitations during minimally-invasive surgical procedures and to enhance the capabilities of surgeons during open surgeries.AI is widely being applied in surgical robots and is also used with machine vision to analyze scans and detect complex cases. While performing surgeries in delicate areas of the human body, robotic surgeries are more effective than manually performed surgeries.To meet healthcare needs, many technology companies are providing innovative robotic solutions. For example, in 2020, Accuracy Incorporated, a US-based company that develops, manufactures, and sells radiotherapy systems for alternative cancer treatments, launched a device called CyberKnife S7 System, which combines speed, advanced precision, and AI-driven motion tracking for stereotactic radiosurgery and stereotactic body radiation therapy treatment. In August 2021, Nurosene Health Inc., a health tech company focused on the mental wellness of people headquartered in Toronto, Canada, acquired Netramark Corp.This acquisition will advance Nurosene’s product capabilities for better brain health by utilizing the machine learning technologies of Netramark Corp. NetraMark Corp is an AI and pharma tech company that develops AI and machine learning solutions for pharmaceutical companies. The countries covered in the Artificial Intelligence in Healthcare Market market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Read the full report: https://www.reportlinker.com/p06282662/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

Yahoo Finance senior health reporter Anjalee Khemlani looks at the FDA linking myocarditis to Novavax's COVID-19 vaccine, in addition to the rise in monkeypox cases in the U.S.

The FDA suggested Friday there could be a link between Novavax's Covid vaccine and heart inflammation, and NVAX stock plummeted.

(Bloomberg) -- Novavax Inc. slumped 20% on Friday after US regulators raised concerns over the biotech’s much-anticipated Covid-19 vaccine. Most Read from BloombergOne-Third of Americans Making $250,000 Live Paycheck-to-Paycheck, Survey FindsTesla Pauses Hiring as Musk Aims for 10% Staff Cut, Reuters Says‘Most Clever Oligarch’ Severed His $37 Billion Fortune From Russian RootsElon Musk’s Ultimatum to Tesla Execs: Return to the Office or Get OutStocks Resume Weekly Losses as Jobs Fuel Rate Bets:

These big names are down — but certainly not out.

The Dow Jones fell on strong jobs data. Tesla stock plunged on an Elon Musk move. Apple stock crumbled. Amazon fell after an executive quit.

In the world of stock legends, Ken Fisher stands out. The legendary investor founded his private financial advisory firm, Fisher Investments, in 1979, with just $250 in seed money. Today, Fisher’s company manages over $195 billion in total assets, and his personal net work exceeds $5 billion. Fisher has cast his eye on current market conditions. In recent published note, Fisher points out the obvious headwinds in the current environment: “Fear of the impact of the tragic, grinding war in Ukraine

Yahoo Finance auto reporter Pras Subramanian breaks down data from a new report indicating depressed U.S. auto sales amid rising inflation and interest rates.

(Reuters) -Dave Clark, the executive who made Amazon.com Inc into a worldwide delivery behemoth, is stepping down as chief executive of the online retailer's consumer business to pursue other opportunities, the company said on Friday. Amazon CEO Andy Jassy said he expects to name a replacement in the next few weeks and that the company has work ahead "to get to where we ultimately want to be" in the division Clark ran. The departure further solidifies a changing of the guard at Amazon, which for years had veteran ranks under founder Jeff Bezos.

It was a tough day for high-growth stocks, as a hot jobs number stoked inflation fears even as Elon Musk warned about the global economy.

See who joins Nvidia and GOOGL on this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.

Oil rig numbers have climbed, but producers remain reluctant to deliver more oil, focusing instead on oil stock investors.

There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met with resounding praise or forceful discontent. Going beyond the argument that you get more for your money, even minor price appreciation can result in massive percentage gains. However, some investors prefer to avoid these stocks entirely, as the fact that shares are trading at such depressed level

Genetic medical testing specialist Invitae (NYSE: NVTA) didn't pass the investment test for one researcher late on Thursday. After market hours on Thursday, financial services company Piper Sandler initiated coverage of Invitae stock. "We think germline testing is becoming more commoditized and Invitae has a late start to somatic cancer," the prognosticator wrote in a research note, referring to two types of genetic screening for cancer.

Don’t bail on stocks. Just choose them wisely.

Jas Thandi, Aon Partner of Portfolio Strategy, and WisdomTree Global CIO Jeremy Schwartz sit down with Yahoo Finance Live to talk about how markets are handling the Fed's raised interest rates, alternative investments, and rising prices in oil commodities.

Yahoo Finance Live checks out several stocks tied to leading industry stories, including American Airlines' decision to raise guidance amid the current travel boom and Boeing facing a two-year delay for its 737 jetliner re-designs.

Shares of Novavax Inc. tumbled 22.9% in trading on Friday after the Food and Drug Administration published a

Piper Sandler is scared of a computer memory glut, but Micron's stock price is cheap enough to already factor that in.

FDA briefing documents in advance of next week's advisory committee meeting highlighted potential safety issues with Novavax's COVID-19 vaccine.

'Multiple events' of heart inflammation were reported after administering the Covid-19 vaccine, especially among younger men, according to the FDA.